Thrombectomy for Stroke (ESCAPE-MeVO Trial)

Palo Alto (17 mi)

Overseen byMayank Goyal, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: N/A

Waitlist Available

Sponsor: Dr. Michael D Hill

Trial Summary

What is the purpose of this trial?This trial tests whether removing blood clots from medium-sized brain vessels helps stroke patients. The procedure uses a special device to pull out the clot and restore blood flow. It targets patients with sudden strokes caused by clots in medium-sized vessels.

Eligibility Criteria

This trial is for adults over 18 who've had a stroke caused by a medium-sized blood clot in the brain, and can start treatment within 12 hours. They must have certain symptoms and imaging results that show they could benefit from EVT. People with severe other illnesses, those already in another trial, or with specific poor health indicators like low ASPECTS scores aren't eligible.

Inclusion Criteria

I have had a severe stroke with an NIHSS score over 5.

I am 18 years old or older.

I am eligible for an emergency procedure to remove a blood clot in my brain.

I have a confirmed MeVO that can be treated with a procedure, as shown by special brain scans.

Exclusion Criteria

I live in a nursing home or need daily help with personal care.

Treatment Details

The ESCAPE-MeVO Trial is testing if adding endovascular thrombectomy (EVT) to standard medical care improves outcomes for patients with ischemic strokes due to medium vessel occlusions. Participants are randomly assigned to receive either just standard care or standard care plus EVT within 12 hours of symptom onset.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: endovascular thrombectomyExperimental Treatment1 Intervention

All participants will receive the best standard of medical care according to modern acute stroke care guidelines. In the intervention/experimental arm, participants will be treated with endovascular thrombectomy with a Solitaire device (Medtronic) as the first line approach. The trial mandates that the first attempt is performed with a Solitaire X device (3mm, 4mm or 6mm diameter devices; Medtronic). The remaining treatment technique is left to the discretion of the treating neurointerventionalist. Secondary devices may be used if success is not achieved after use of the first device.

Group II: best medical carePlacebo Group1 Intervention

All patients will receive the best standard of medical care according to modern acute stroke care guidelines All patients including the ones in control arm will receive the best standard of medical care according to modern acute stroke care guidelines. The model will be the Canadian best practices guidelines for acute stroke care. These are very similar to the guidelines of the American Stroke Association and the European Stroke Organization. All participants are expected to be admitted to hospital as part of routine standard of care.It is expected that all participants will undergo a routine work-up for the mechanism of their stroke and be treated appropriately and definitively.